SCHEDULE: RTW Fund Group Discloses Stake in Yarrow Bioscience

RTW Fund Group GP, LLC and Roderick Wong, M.D. have reported beneficial ownership of 9.99% of Yarrow Bioscience, Inc. common stock.

Summary

• RTW Fund Group GP, LLC and Roderick Wong, M.D. have jointly filed a Schedule 13G, indicating their beneficial ownership of Yarrow Bioscience, Inc. common stock.
• The filing reports a total of 266,307 shares beneficially owned, representing 9.99% of the company's outstanding common stock.
• This ownership level is calculated based on 2,669,788 shares outstanding as of July 29, 2026.
• The Reporting Persons have stated that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about the company itself.

Positives

• RTW Fund Group and Roderick Wong, M.D. have disclosed a significant stake, indicating confidence or strategic interest in Yarrow Bioscience.
• The filing confirms that the shares were acquired in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures associated with beneficial ownership filings.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The reporting persons' intent is to hold shares in the ordinary course of business.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates RTW Fund Group's strategic interest in Yarrow Bioscience, a biotechnology company.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially signaling increased interest or stability in the stock.

Next Steps

• RTW Fund Group GP, LLC and Roderick Wong, M.D. will file amendments to this statement as necessary.

Key Dates

Keywords

Yarrow Bioscience, RTW Fund Group, Roderick Wong, Schedule 13G, Beneficial Ownership, Investment, SEC Filing